EKF Diagnostics Holdings plc

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Africa, Asia, and internationally. It offers DiaSpect Tm and DiaSpect T hemoglobin analyzers; DiaSpect Hemoglobin T Low to determine low levels of hemoglobin in plasma and serum specimens, aqueous solutions, or stored or banked erythrocytes; Hemo Control, a point-of-care hemoglobin analyzer that provides quantitative and lab quality hemoglobin results; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. The company also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab A1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test A1c for the monitoring and management of diabetes in a point-of-care setting; and STAT-Site M Beta-hydroxybutyrate analyzer. In addition, it offers Creamatocrit Plus, an analyzer for detecting the lipid concentration and calorific density in mothers' milk; QuPID and True20 pregnancy tests; and Lactate Scout 4, a lactate analyzer. Further, the company offers Altair 240, a chemistry analyzer; Excel, a semi-automated chemistry analyzer; Micro 12, a micro centrifuge for clinical, molecular, and bacteriological applications; reagents, calibrators, standards, and controls; immunoassay kits; Hema-Screen Serology, an analyzer dependent for early detection of colorectal cancer; sTNFRr1, a predictive marker of end stage renal disease; and Uri-Trak 120 urine analyzer. Additionally, it provides contract manufacturing services, as well as services and distributes third party company's products. It sells its products directly to hospitals, laboratories, and government agencies, as well as through a network of distributors. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom. Show More...